$ALXO
ALX ONCOLOGY HOLDINGS INC

2024 Q4 Form 10-Q Financial Statement

#000095017024123290 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.096M
YoY Change -18.83%
% of Gross Profit
Research & Development $26.47M
YoY Change -42.16%
% of Gross Profit
Depreciation & Amortization $224.0K
YoY Change 6.67%
% of Gross Profit
Operating Expenses $32.57M
YoY Change -38.87%
Operating Profit -$32.57M
YoY Change -38.87%
Interest Expense $446.0K
YoY Change 14.07%
% of Operating Profit
Other Income/Expense, Net $3.000K
YoY Change -400.0%
Pretax Income -$30.71M
YoY Change -39.78%
Income Tax
% Of Pretax Income
Net Earnings -$30.71M
YoY Change -39.78%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58
Diluted Earnings Per Share -$0.58
COMMON SHARES
Basic Shares Outstanding 52.74M 52.67M
Diluted Shares Outstanding 52.69M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.6M
YoY Change -21.8%
Cash & Equivalents $16.10M
Short-Term Investments $132.5M
Other Short-Term Assets $1.225M
YoY Change -85.59%
Inventory
Prepaid Expenses $1.150M
Receivables
Other Receivables
Total Short-Term Assets $155.9M
YoY Change -21.69%
LONG-TERM ASSETS
Property, Plant & Equipment $3.112M
YoY Change -13.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $14.04M
YoY Change 119.31%
Other Assets $12.67M
YoY Change 15.37%
Total Long-Term Assets $29.82M
YoY Change 41.76%
TOTAL ASSETS
Total Short-Term Assets $155.9M
Total Long-Term Assets $29.82M
Total Assets $185.7M
YoY Change -15.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.891M
YoY Change -39.3%
Accrued Expenses $22.97M
YoY Change 8.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $32.34M
YoY Change -7.97%
LONG-TERM LIABILITIES
Long-Term Debt $9.835M
YoY Change 2.72%
Other Long-Term Liabilities $6.733M
YoY Change 1.43%
Total Long-Term Liabilities $16.57M
YoY Change 2.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.34M
Total Long-Term Liabilities $16.57M
Total Liabilities $48.91M
YoY Change -4.76%
SHAREHOLDERS EQUITY
Retained Earnings -$592.0M
YoY Change 34.29%
Common Stock $728.2M
YoY Change 19.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $136.8M
YoY Change
Total Liabilities & Shareholders Equity $185.7M
YoY Change -15.63%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$30.71M
YoY Change -39.78%
Depreciation, Depletion And Amortization $224.0K
YoY Change 6.67%
Cash From Operating Activities -$25.38M
YoY Change -18.56%
INVESTING ACTIVITIES
Capital Expenditures $149.0K
YoY Change -111.46%
Acquisitions
YoY Change
Other Investing Activities $25.84M
YoY Change 124.52%
Cash From Investing Activities $25.69M
YoY Change 100.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 251.0K
YoY Change -328.18%
NET CHANGE
Cash From Operating Activities -25.38M
Cash From Investing Activities 25.69M
Cash From Financing Activities 251.0K
Net Change In Cash 568.0K
YoY Change -103.08%
FREE CASH FLOW
Cash From Operating Activities -$25.38M
Capital Expenditures $149.0K
Free Cash Flow -$25.53M
YoY Change -14.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001810182
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities
CY2024Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39386
dei Entity Registrant Name
EntityRegistrantName
ALX ONCOLOGY HOLDINGS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0642577
dei Entity Address Address Line1
EntityAddressAddressLine1
323 Allerton Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
466-7125
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ALXO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52743104
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16102000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22406000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
132472000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
160330000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7321000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5923000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
155895000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
188659000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3112000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3589000
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
14036000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
35411000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12672000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14894000
CY2024Q3 us-gaap Assets
Assets
185715000
CY2023Q4 us-gaap Assets
Assets
242553000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7891000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8591000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
63000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
543000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24386000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
26867000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32340000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36001000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9835000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9639000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6733000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7201000
CY2024Q3 us-gaap Liabilities
Liabilities
48908000
CY2023Q4 us-gaap Liabilities
Liabilities
52841000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52743104
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52743104
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49951989
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49951989
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
53000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
728150000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
675678000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
563000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
256000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-591959000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-486272000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
136807000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
189712000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
185715000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242553000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26471000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45766000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92841000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100011000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6096000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7509000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19013000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22244000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
32567000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
53275000
us-gaap Operating Expenses
OperatingExpenses
111854000
us-gaap Operating Expenses
OperatingExpenses
122255000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32567000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53275000
us-gaap Operating Income Loss
OperatingIncomeLoss
-111854000
us-gaap Operating Income Loss
OperatingIncomeLoss
-122255000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2303000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2677000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7488000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7654000
CY2024Q3 us-gaap Interest Expense
InterestExpense
446000
CY2023Q3 us-gaap Interest Expense
InterestExpense
391000
us-gaap Interest Expense
InterestExpense
1302000
us-gaap Interest Expense
InterestExpense
1150000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
418000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-30707000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50990000
us-gaap Net Income Loss
NetIncomeLoss
-105687000
us-gaap Net Income Loss
NetIncomeLoss
-115333000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.82
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52693878
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52693878
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41147938
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41147938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51544501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51544501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40963015
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40963015
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-30707000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50990000
us-gaap Net Income Loss
NetIncomeLoss
-105687000
us-gaap Net Income Loss
NetIncomeLoss
-115333000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
636000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
86000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
307000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
619000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30071000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50904000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-105380000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-114714000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
189712000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
237000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7031000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-228000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35581000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
164195000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
861000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
306000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7252000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-101000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39399000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
159317000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
534000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6952000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
636000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-30707000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
136807000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
263464000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6351000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30184000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240388000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
112000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
338000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6237000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-224000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34159000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212692000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6964000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
86000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50990000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
168752000
us-gaap Profit Loss
ProfitLoss
-105687000
us-gaap Profit Loss
ProfitLoss
-115333000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
658000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
629000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
1312000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
920000
us-gaap Share Based Compensation
ShareBasedCompensation
21235000
us-gaap Share Based Compensation
ShareBasedCompensation
19552000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3920000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4606000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
196000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
186000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1418000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4310000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2170000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4215000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-637000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4942000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
-480000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
-1385000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1730000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
6491000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1575000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1987000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89866000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90686000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
102962000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
171619000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
156422000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
234068000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
387000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1126000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
53073000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61323000
alxo Commission And Offering Costs
CommissionAndOfferingCosts
800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29302000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1632000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
306000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
338000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
751000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
325000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30489000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6304000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-29238000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22472000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48888000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16168000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19650000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
1211000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
1376000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1309000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1187000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16102000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19584000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16168000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19650000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including, but not limited to, those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, fair value of investments and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
161521000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215822000
CY2024Q3 us-gaap Cash
Cash
1100000
CY2023Q4 us-gaap Cash
Cash
2300000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
147485000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
180411000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14036000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
35411000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
161521000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215822000
CY2024Q3 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2023Q3 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1200000
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1000000
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
5900000
alxo Impairment Losses On Available For Sale Investments
ImpairmentLossesOnAvailableForSaleInvestments
0
alxo Impairment Losses On Available For Sale Investments
ImpairmentLossesOnAvailableForSaleInvestments
0
CY2024Q3 alxo Prepaid Clinical Expenses
PrepaidClinicalExpenses
2917000
CY2023Q4 alxo Prepaid Clinical Expenses
PrepaidClinicalExpenses
3049000
CY2024Q3 alxo Interest And Investment Receivables Current
InterestAndInvestmentReceivablesCurrent
1183000
CY2023Q4 alxo Interest And Investment Receivables Current
InterestAndInvestmentReceivablesCurrent
996000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1150000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
830000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
846000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
609000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1225000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
439000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7321000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5923000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5003000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4826000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1891000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1237000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3112000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3589000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4234000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4847000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2966000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2405000
CY2024Q3 alxo Other Assets Noncurrent Other
OtherAssetsNoncurrentOther
200000
CY2023Q4 alxo Other Assets Noncurrent Other
OtherAssetsNoncurrentOther
200000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12672000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14894000
CY2024Q3 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
10144000
CY2023Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
8873000
CY2024Q3 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
7007000
CY2023Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
9543000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4643000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6067000
CY2024Q3 alxo Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
189000
CY2023Q4 alxo Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
179000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2403000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2205000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24386000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
26867000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has non-cancelable operating leases for its offices located in the U.S. As of September 30, 2024, these leases expire on various dates between 2026 and 2030.
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain lease agreements include one or more options to renew, with renewal terms that can extend the lease up to two years after expiration.
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
319000
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
264000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
1305000
CY2024Q3 us-gaap Finance Lease Liability Payments Due In Next Rolling Twelve Months
FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
1056000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1187000
CY2024Q3 us-gaap Finance Lease Liability Payments Due In Rolling Year Two
FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
1056000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
912000
CY2024Q3 us-gaap Finance Lease Liability Payments Due In Rolling Year Three
FinanceLeaseLiabilityPaymentsDueInRollingYearThree
616000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
939000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
1130000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5792000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2992000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1161000
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
100000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4631000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
2892000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
923000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
943000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3708000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1949000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4631000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
2892000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.085
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
311000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
317000
us-gaap Operating Lease Cost
OperatingLeaseCost
933000
us-gaap Operating Lease Cost
OperatingLeaseCost
952000
CY2024Q3 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
131000
CY2023Q3 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
128000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
429000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
347000
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
254000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
114000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
700000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
338000
CY2024Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
63000
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
9000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
160000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11000
CY2024Q3 us-gaap Lease Cost
LeaseCost
762000
CY2023Q3 us-gaap Lease Cost
LeaseCost
570000
us-gaap Lease Cost
LeaseCost
2236000
us-gaap Lease Cost
LeaseCost
1656000
us-gaap Operating Lease Payments
OperatingLeasePayments
948000
us-gaap Operating Lease Payments
OperatingLeasePayments
931000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
169000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
751000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
325000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1309000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1187000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
435000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5217000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4948000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
10600000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q3 alxo Term Loan Non Current
TermLoanNonCurrent
10600000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
616000
CY2024Q3 alxo Term Loan Unamortized Final Payment
TermLoanUnamortizedFinalPayment
149000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9835000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52743104
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49951989
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13517990
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6952000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6964000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21235000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19552000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-30707000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50990000
us-gaap Net Income Loss
NetIncomeLoss
-105687000
us-gaap Net Income Loss
NetIncomeLoss
-115333000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52693878
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52693878
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41147938
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41147938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51544501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51544501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40963015
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40963015
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.82
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11491065
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11491065
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10199289
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10199289
CY2024Q3 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
3665000
CY2024Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
1874000
CY2024Q3 us-gaap Purchase Obligation Due In Second And Third Year
PurchaseObligationDueInSecondAndThirdYear
1741000
CY2024Q3 us-gaap Purchase Obligation Due In Fourth And Fifth Year
PurchaseObligationDueInFourthAndFifthYear
50000
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
3665000
CY2024Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
1874000
CY2024Q3 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
1741000
CY2024Q3 us-gaap Contractual Obligation Due In Fourth And Fifth Year
ContractualObligationDueInFourthAndFifthYear
50000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123290-index-headers.html Edgar Link pending
0000950170-24-123290-index.html Edgar Link pending
0000950170-24-123290.txt Edgar Link pending
0000950170-24-123290-xbrl.zip Edgar Link pending
alxo-20240930.htm Edgar Link pending
alxo-20240930.xsd Edgar Link pending
alxo-ex10_1.htm Edgar Link pending
alxo-ex31_1.htm Edgar Link pending
alxo-ex31_2.htm Edgar Link pending
alxo-ex32_1.htm Edgar Link pending
alxo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
alxo-20240930_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable